Trial Results Not Expected to Hurt Merck's Vytorin, Zetia

Merck & Co. has determined there is no need to write down the value of blockbuster cholesterol drugs Vytorin and Zetia, suggesting the results of a long-running clinical trial results won’t hurt their value.



from WSJ.com: US Business http://ift.tt/1wbc0eQ

via IFTTT